Celsion Corporation is a fully integrated biopharmaceutical company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies. Our lead product candidate is ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in a phase 3 trial combined with RFA for the treatment of hepatocellular carcinoma. It is also in a phase 2 study for the treatment of recurrent chest wall breast cancer. Second in our pipeline is GEN-1, a DNA-mediated immunotherapy for the localized treatment of ovarian cancer.
Celsion has 3 platform technologies providing the basis for the development of a range of therapeutics for difficult-to-treat forms of cancers. With these technologies we are working to develop and commercialize more efficient, effective, and targeted oncology therapies, maximizing efficacy while minimizing side effects common to cancer treatments.
Revenue (Q1, 2018)
Net income (Q1, 2018)
EBIT (Q1, 2018)
Market capitalization (22-Jun-2018)
Closing share price (22-Jun-2018)
|USD||Q2, 2014||Q3, 2014||Q1, 2015||Q2, 2015||Q3, 2015||Q1, 2016||Q2, 2016||Q3, 2016||Q1, 2017||Q3, 2017||Q1, 2018|
|125 k||125 k|
General and administrative expense
|2.3 m||2 m||2 m||1.8 m||1.5 m||1.9 m||1.5 m||1.5 m||1.5 m||1.2 m||1.7 m|
|3.2 m||4.6 m||4.5 m||3.6 m||2.9 m||3.4 m||3.3 m||4.2 m||3.5 m||3.3 m||2.7 m|
Operating expense total
|5.5 m||6.7 m||6.5 m||5.4 m||4.4 m||5.3 m||4.9 m||5.7 m||4.9 m||4.5 m||4.4 m|